Chapter 5 Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) infection has an estimated global incidence of 33 million cases in children younger than 5 years, with 10% requiring hospital admission and up to 199,000 dying of the disease. There is growing evidence that severe infantile RSV bronchiolitis, a condition characteris...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Online |
| Idioma: | inglês |
| Publicado em: |
European Respiratory Society
2021
|
| Assuntos: | |
| Acesso em linha: | https://library.oapen.org/handle/20.500.12657/47857 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1869516678374621184 |
|---|---|
| author | Jha, Akhilesh Jarvis, Hannah Fraser, Clementine Openshaw, Peter |
| author_browse | Fraser, Clementine Jarvis, Hannah Jha, Akhilesh Openshaw, Peter |
| author_facet | Jha, Akhilesh Jarvis, Hannah Fraser, Clementine Openshaw, Peter |
| author_sort | Jha, Akhilesh |
| collection | Directory of Open Access Books |
| description | Respiratory syncytial virus (RSV) infection has an estimated global incidence of 33 million cases in children younger than 5 years, with 10% requiring hospital admission and up to 199,000 dying of the disease. There is growing evidence that severe infantile RSV bronchiolitis, a condition characterised by an inflammatory reaction to the virus, is associated with later childhood wheeze in some vulnerable children; however, a direct causal relationship with asthma has not yet been established. It is also increasingly recognised as a cause of morbidity and mortality in those with underlying airway disease, immunocompromise and frail elderly persons. Novel molecular based diagnostic tools are becoming established but treatment largely remains supportive, with palivizumab being the only licensed agent currently available for passive prophylaxis of selected pre-term infants. Whilst effective treatments remain elusive, there is optimism about the testing of novel antiviral drugs and the development of vaccines that may induce long-lasting immunity without the risk of disease augmentation. |
| format | Online |
| id | doab-20.500.12854ir-64632 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | European Respiratory Society |
| publisherStr | European Respiratory Society |
| record_format | ojs |
| spelling | doab-20.500.12854ir-646322025-01-28T05:18:56Z Chapter 5 Respiratory Syncytial Virus Jha, Akhilesh Jarvis, Hannah Fraser, Clementine Openshaw, Peter viral lung disease, RSV, paediatric infections, bronchiolitis, mucosal immunity thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders Respiratory syncytial virus (RSV) infection has an estimated global incidence of 33 million cases in children younger than 5 years, with 10% requiring hospital admission and up to 199,000 dying of the disease. There is growing evidence that severe infantile RSV bronchiolitis, a condition characterised by an inflammatory reaction to the virus, is associated with later childhood wheeze in some vulnerable children; however, a direct causal relationship with asthma has not yet been established. It is also increasingly recognised as a cause of morbidity and mortality in those with underlying airway disease, immunocompromise and frail elderly persons. Novel molecular based diagnostic tools are becoming established but treatment largely remains supportive, with palivizumab being the only licensed agent currently available for passive prophylaxis of selected pre-term infants. Whilst effective treatments remain elusive, there is optimism about the testing of novel antiviral drugs and the development of vaccines that may induce long-lasting immunity without the risk of disease augmentation. 2021-04-16T02:01:46Z 2021-04-16T02:01:46Z 2021-04-15T11:37:39Z 2016 chapter https://library.oapen.org/handle/20.500.12657/47857 https://directory.doabooks.org/handle/20.500.12854/64632 eng open access image/jpeg image/jpeg Attribution-NonCommercial 4.0 International Attribution-NonCommercial 4.0 International https://library.oapen.org/bitstream/20.500.12657/47857/1/Bookshelf_NBK442240.pdf https://library.oapen.org/bitstream/20.500.12657/47857/1/Bookshelf_NBK442240.pdf European Respiratory Society e4ffdc34-97a1-4c5b-992f-04853e6f8983 SARS, MERS and other Viral Lung Infections Wellcome Trust d859fbd3-d884-4090-a0ec-baf821c9abfd Wellcome 38 Sheffield open access |
| spellingShingle | viral lung disease, RSV, paediatric infections, bronchiolitis, mucosal immunity thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders Jha, Akhilesh Jarvis, Hannah Fraser, Clementine Openshaw, Peter Chapter 5 Respiratory Syncytial Virus |
| title | Chapter 5 Respiratory Syncytial Virus |
| title_full | Chapter 5 Respiratory Syncytial Virus |
| title_fullStr | Chapter 5 Respiratory Syncytial Virus |
| title_full_unstemmed | Chapter 5 Respiratory Syncytial Virus |
| title_short | Chapter 5 Respiratory Syncytial Virus |
| title_sort | chapter 5 respiratory syncytial virus |
| topic | viral lung disease, RSV, paediatric infections, bronchiolitis, mucosal immunity thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders |
| topic_facet | viral lung disease, RSV, paediatric infections, bronchiolitis, mucosal immunity thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders |
| url | https://library.oapen.org/handle/20.500.12657/47857 |
| work_keys_str_mv | AT jhaakhilesh chapter5respiratorysyncytialvirus AT jarvishannah chapter5respiratorysyncytialvirus AT fraserclementine chapter5respiratorysyncytialvirus AT openshawpeter chapter5respiratorysyncytialvirus |